MX342791B - Ensayo elisa para la detección de vegf. - Google Patents

Ensayo elisa para la detección de vegf.

Info

Publication number
MX342791B
MX342791B MX2014011461A MX2014011461A MX342791B MX 342791 B MX342791 B MX 342791B MX 2014011461 A MX2014011461 A MX 2014011461A MX 2014011461 A MX2014011461 A MX 2014011461A MX 342791 B MX342791 B MX 342791B
Authority
MX
Mexico
Prior art keywords
vegf
diagnostic
prognostic index
elisa
pathologies
Prior art date
Application number
MX2014011461A
Other languages
English (en)
Inventor
Kyu H Hong
Johnny Gutierrez
Yu-Ju G Meng
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX342791B publication Critical patent/MX342791B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors

Abstract

La presente invención se refiere a la actividad del factor de crecimiento endotelial vascular (VEGF) en el torrente sanguíneo de un paciente o en otra muestra biológica puede servir como índice de diagnóstico y pronóstico para el cáncer, diabetes, afecciones cardíacas y otras patologías. Los métodos de ensayo ELISA de tipo "sándwich" que utilizan anticuerpos y los kits de detección de VEGF como antígeno se proporcionan para detectar los tipos de niveles de VEGF en muestras biológicas de modelos animales y pacientes humanos y pueden ser utilizados como índice de diagnóstico y pronóstico.
MX2014011461A 2006-10-04 2009-04-02 Ensayo elisa para la detección de vegf. MX342791B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82820306P 2006-10-04 2006-10-04

Publications (1)

Publication Number Publication Date
MX342791B true MX342791B (es) 2016-10-12

Family

ID=39301650

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2009003562A MX2009003562A (es) 2006-10-04 2007-10-03 Ensayo elisa para la deteccion de vegf.
MX2014011461A MX342791B (es) 2006-10-04 2009-04-02 Ensayo elisa para la detección de vegf.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2009003562A MX2009003562A (es) 2006-10-04 2007-10-03 Ensayo elisa para la deteccion de vegf.

Country Status (25)

Country Link
US (5) US20080227119A1 (es)
EP (3) EP2069798B1 (es)
JP (1) JP6025294B2 (es)
KR (2) KR101720887B1 (es)
CN (2) CN103454434B (es)
AR (2) AR063125A1 (es)
AU (1) AU2007319654B2 (es)
BR (1) BRPI0715239A2 (es)
CA (1) CA2663012C (es)
DK (2) DK2069798T3 (es)
ES (2) ES2470682T3 (es)
HK (3) HK1130090A1 (es)
HR (1) HRP20140675T1 (es)
HU (1) HUE030082T2 (es)
IL (1) IL197374A (es)
MX (2) MX2009003562A (es)
NZ (1) NZ613646A (es)
PL (2) PL2457929T3 (es)
PT (1) PT2069798E (es)
RS (1) RS53387B (es)
RU (2) RU2517301C2 (es)
SI (2) SI2069798T1 (es)
TW (2) TWI429654B (es)
WO (1) WO2008060777A2 (es)
ZA (1) ZA200901518B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050009110A1 (en) * 2003-07-08 2005-01-13 Xiao-Jia Chang Methods of producing antibodies for diagnostics and therapeutics
RS53387B (en) 2006-10-04 2014-10-31 Genentech, Inc. ELISA FOR VEGF
WO2011031986A1 (en) 2009-09-10 2011-03-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer, National Institutes Of Health Assays for soluble il-15 receptor alpha
JP2013538338A (ja) * 2010-07-19 2013-10-10 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 抗癌治療への応答可能性の増大した患者を同定する方法
SG187018A1 (en) * 2010-07-19 2013-02-28 Hoffmann La Roche Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
CN102207504A (zh) * 2011-03-23 2011-10-05 北京华创远航科技有限公司 一种酶联检测试剂盒及其制备方法
CN102435743B (zh) * 2011-09-15 2014-10-15 北京健平九星生物医药科技有限公司 一种酶联检测试剂盒及其制备方法
CN102426240B (zh) * 2011-09-19 2014-10-15 北京健平金星生物科技有限公司 一种酶联检测试剂盒及其制备方法
MX349003B (es) 2011-12-19 2017-07-06 Hoffmann La Roche Metodo para la deteccion del asociado de union libre de un aglutinante multiespecifico.
SG11201403927XA (en) 2012-01-13 2014-08-28 Genentech Inc Biological markers for identifying patients for treatment with vegf antagonists
WO2013113663A1 (en) * 2012-02-01 2013-08-08 F. Hoffmann-La Roche Ag Method for the detection of a binding partner of a multispecific binder
CN102645530B (zh) * 2012-04-06 2014-06-18 上海蓝怡科技有限公司 甲状腺素酶联免疫体外诊断试剂盒中酶结合物稀释液的制备方法
KR20150038046A (ko) 2012-07-13 2015-04-08 에프. 호프만-라 로슈 아게 다중특이적 결합체의 탐지 방법
RU2016107435A (ru) 2013-09-13 2017-10-18 Дженентек, Инк. Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты
NZ756749A (en) 2013-09-13 2022-05-27 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
US9901579B2 (en) 2013-10-17 2018-02-27 Sartar Therapeutics Ltd Compositions comprising phosphodiesterase inhibitors for use in the treatment of a solid tumor in a human patient
RU2589286C1 (ru) * 2015-02-03 2016-07-10 Федеральное государственное бюджетное научное учреждение "Томский научно-исследовательский институт онкологии" (Томский НИИ онкологии) Способ прогнозирования исхода заболевания у больных метастатическим раком почки
RU2622005C2 (ru) * 2015-11-24 2017-06-08 Федеральное государственное бюджетное учреждение "Государственный научный центр дерматовенерологии и косметологии" Минздрава России (ФГБУ ГНЦДК Минздрава России) СПОСОБ ПОЛУЧЕНИЯ СЕЛЕКТИВНОГО ИММУНОСОРБЕНТА ДЛЯ УДАЛЕНИЯ АНТИТЕЛ-IgG К ДЕСМОГЛЕИНУ 3 ТИПА ИЗ СЫВОРОТКИ КРОВИ БОЛЬНЫХ ПУЗЫРЧАТКОЙ
CN105510595A (zh) * 2015-12-01 2016-04-20 邹检平 基于量子点CdTe检测人血清中VEGF浓度的试剂盒及其使用方法
JP2019523404A (ja) 2016-07-15 2019-08-22 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 全ｖｅｇｆ−ａのレベルを検出するための方法及び手段
CN107167588A (zh) * 2017-03-28 2017-09-15 马杰 用于检测血清中血管内皮生长因子的抗体及试剂盒
RU2732013C1 (ru) * 2019-12-11 2020-09-10 Федеральное бюджетное учреждение науки "Государственный научный центр прикладной микробиологии и биотехнологии" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ПМБ) Способ сенсибилизации планшета для иммуноферментного анализа нерастворимыми белковыми антигенами
CN111044734A (zh) * 2019-12-30 2020-04-21 上海复星长征医学科学有限公司 一种用于检测血管内皮生长因子的检测试剂盒及其制备方法和使用方法
KR20220157228A (ko) 2021-05-20 2022-11-29 대한민국(질병관리청장) 보툴리눔 독소 a에 특이적인 항체, 이를 생산하는 하이브리도마 세포주, 및 이를 이용한 보툴리눔 독소 a 진단 키트
CN117805397A (zh) * 2024-02-29 2024-04-02 军科正源（北京）药物研究有限责任公司 检测游离vegf的方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE337223B (es) 1967-05-23 1971-08-02 Pharmacia Ab
US3720760A (en) 1968-09-06 1973-03-13 Pharmacia Ab Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples
GB1319315A (en) 1969-06-19 1973-06-06 Citizen Watch Co Ltd Calendar timepiece
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
US7005505B1 (en) * 1995-08-25 2006-02-28 Genentech, Inc. Variants of vascular endothelial cell growth factor
US6020473A (en) 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
DE19532347A1 (de) 1995-09-04 1997-03-06 Bayer Ag 4-Thiocarbamoyl-1-(3-pyrazolyl)-pyrazole
US6750044B1 (en) * 1996-10-17 2004-06-15 Genentech, Inc. Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids
EP0973804B1 (en) 1997-04-07 2006-12-27 Genentech, Inc. Anti-vegf antibodies
JP3591264B2 (ja) * 1997-12-24 2004-11-17 富士レビオ株式会社 Ｖｅｇｆ１２１特異的モノクローナル抗体及び測定方法
US7078382B1 (en) 1999-11-02 2006-07-18 Genentech, Inc. Modulation of eNOS activity and therapeutic uses thereof
JP4620312B2 (ja) * 1999-11-16 2011-01-26 ジェネンテック， インコーポレイテッド Ｖｅｇｆに対するエライザ
RU2271010C2 (ru) * 2004-03-31 2006-02-27 Общество с ограниченной ответственностью "Фирма МонА" Способ иммуноферментного анализа для определения фактора виллебранда, моноклональное антитело к фактору виллебранда (варианты) и штамм гибридных культивируемых клеток животных mus. musculus l. - продуцент моноклональных антител к фактору виллебранда (варианты)
US20060257901A1 (en) * 2005-03-24 2006-11-16 Beth Israel Deaconess Medical Center Methods of diagnosing fetal trisomy 13 or a risk of fetal trisomy 13 during pregnancy
RS53387B (en) 2006-10-04 2014-10-31 Genentech, Inc. ELISA FOR VEGF

Also Published As

Publication number Publication date
WO2008060777A3 (en) 2008-07-10
AR107561A2 (es) 2018-05-09
AR063125A1 (es) 2008-12-30
CN101523220B (zh) 2016-09-21
SI2069798T1 (sl) 2014-07-31
US20160033517A1 (en) 2016-02-04
ES2470682T3 (es) 2014-06-24
AU2007319654A1 (en) 2008-05-22
RU2009116611A (ru) 2010-11-10
US9625462B2 (en) 2017-04-18
IL197374A (en) 2016-11-30
CA2663012C (en) 2017-06-27
MX2009003562A (es) 2009-04-15
BRPI0715239A2 (pt) 2013-06-25
SI2457929T1 (sl) 2016-09-30
HRP20140675T1 (hr) 2014-10-10
HUE030082T2 (en) 2017-04-28
RU2517301C2 (ru) 2014-05-27
CA2663012A1 (en) 2008-05-22
KR20090091695A (ko) 2009-08-28
PL2069798T3 (pl) 2014-09-30
JP2010506171A (ja) 2010-02-25
AU2007319654B2 (en) 2013-09-12
US9146245B2 (en) 2015-09-29
EP3103812A1 (en) 2016-12-14
TW201406778A (zh) 2014-02-16
EP2069798A2 (en) 2009-06-17
TWI541251B (zh) 2016-07-11
CN103454434A (zh) 2013-12-18
RU2014104113A (ru) 2015-08-10
TWI429654B (zh) 2014-03-11
NZ613646A (en) 2015-03-27
EP2457929A1 (en) 2012-05-30
JP6025294B2 (ja) 2016-11-16
EP2069798B1 (en) 2014-04-16
ZA200901518B (en) 2010-05-26
EP2457929B1 (en) 2016-06-08
HK1130090A1 (en) 2009-12-18
WO2008060777A2 (en) 2008-05-22
EP3103812B1 (en) 2021-07-28
US20130045495A1 (en) 2013-02-21
RS53387B (en) 2014-10-31
TW200823233A (en) 2008-06-01
PL2457929T3 (pl) 2016-12-30
HK1168361A1 (zh) 2012-12-28
CN101523220A (zh) 2009-09-02
US8449885B2 (en) 2013-05-28
US20080227119A1 (en) 2008-09-18
DK2069798T3 (da) 2014-06-16
US20100255515A1 (en) 2010-10-07
KR20150038444A (ko) 2015-04-08
CN103454434B (zh) 2016-08-10
US20170276683A1 (en) 2017-09-28
IL197374A0 (en) 2009-12-24
KR101551984B1 (ko) 2015-09-09
DK2457929T3 (en) 2016-09-05
ES2584322T3 (es) 2016-09-27
KR101720887B1 (ko) 2017-03-28
PT2069798E (pt) 2014-06-24
HK1232236A1 (zh) 2018-01-05

Similar Documents

Publication Publication Date Title
MX2009003562A (es) Ensayo elisa para la deteccion de vegf.
DE60025526D1 (de) Elisa für vegf
WO2006091412A3 (en) Adamts-7 as a biomarker for cancers of epithelial origin
WO2005108989A3 (en) Assay for antibodies
WO2006073682A3 (en) Diagnostic test
JP2009525478A5 (es)
MX2010006484A (es) Composiciones y metodos para detectar anticuerpos de infidelidad de transcripcion (tiab).
TW200600060A (en) Apparatus for the manufacture of medical devices
EP1907845A4 (en) DIAGNOSIS OF ILLNESSES AND SUFFERING BY ANALYSIS OF HISTOPATHOLOGICALLY PREPARED BIOLOGICAL SAMPLES USING LIQUID TISSUE PREPARATIONS
EP2503338A3 (en) CD73 as a biomarker for monitoring development of diseases and assessing the efficacy of therapies
EP2006392A4 (en) METHOD FOR DETERMINING ALZHEIMER'S DISEASE BY DETERMINING THE DEGRADATION RATE OF beta-AMYLOID IN BLOOD AND DIAGNOSTIC REAGENT
EA201590686A1 (ru) Тест на митохондриальную токсичность
Özsoylu et al. (Bio-) Sensors for Skin Grafts and Skin Flaps Monitoring
da Rocha Nogueira et al. Factors associated with microalbuminuria in resistant hypertension
Krivenko et al. Accuracy improvement of noninvasive determination of glucose concentration in human blood
CY1115197T1 (el) Elisa για vegf
DE502004012230D1 (de) Verfahren zur diagnose von erkrankungen unter bestimmung von apolipoprotein c-i
RU2006124937A (ru) Способ прогнозирования течения сахарного диабета 1 типа
Birbrair Pericyte Biology in Different Organs
CY1112415T1 (el) Η πρωτεϊνη serum amyloid p-component (sap, samp) ως προγνωστικος και διαγνωστικος δεικτης για τον προγεννητικο ελεγχο της τρισωμιας 21 (συνδρομο down)
Ghanbari Cancer diagnostics integrated with therapeutics: a comprehensive approach to managing the disease
RU2004136472A (ru) Способ лечения хронических диффузных заболеваний печени
GB0713363D0 (en) Diagnosis and treatment of abnormal blood conditions
이미화 The Elevation Factors Associated with Increased Blood Glucose in Gravida
UA27414U (en) Method for predicting infectious complication in patients with toxico--septic biliary syndrome